Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.

Br J Ophthalmol · 2016 · PMC5256408 · PMID 27030279

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to achieve significanceno p-value reported

Age at start of therapy (0.97), baseline visual acuity score (0.95) and number of ophthalmoscopies and OCT (1.03) were significantly (p<0.05) associated with vision gain (gain of ≥15 letters) at year 1, but injections (ranibizumab) failed to achieve significance ( table 4 A).

also in 299 other papers

did not achieve significanceno p-value reported

Age, baseline visual acuity score and number of ophthalmoscopies and OCT were also significantly (p<0.05) associated with vision maintenance at year 2 ( table 3 B), but injections (ranibizumab) did not achieve significance at year 2.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.